Effect of Prazosin on Blood Lipids and on Thyroid Function in Hypertensive Patients

Velasco, Manuel; Silva, H; Morillo, J.; Pellicer, Rosa; Urbina-Quintana, A.; Hernández-Pieretti, O.

doi:10.1097/00005344-198200042-00008

Cited by 20 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kristensen and Weeke, (25) reported that propranolol therapy in doses of 80-480 mg/d for 30 days period, in 15 euthyroid hypertensive patients causes the total and free T3 as well as TSH concentration to be unchanged with an average increase in total and T4 concentration, and they concluded that propranolol -induced decreased degradation of T4 levels. Velasco et al, (26) concluded that prazocin 1-4 mg/d in 19 patients with hypertension for 12 wks causes increases in TSH and T4 with decrease in T3 levels, but all values remained within the normal ranges. Gumbatov et al, (27) reported that nadolol monotherapy in 20 males with stage 2 hypertension and in a dose of 40-160 mg/d causes insignificant changes in the mean values of TSH and T4 levels, but causes a decrease in T3 concentration at its high baseline value and in a dose greater than 40 mg/day.…”

Section: Discussionmentioning

confidence: 98%

Oxidant / antioxidant status and thyroid function tests in hypertensive patients treated by captopril or valsartan

Othman¹,

Thanoon²

2012

Ann Coll Med Mosul

View full text Add to dashboard Cite

Objectives:To assess, the oxidant / antioxidant status and thyroid function tests in newly diagnosed hypertensive patients and the effect of therapy with captopril or valsartan for 2 months on these parameters in comparison to healthy control subjects. Methods: This study was conducted in Ibn-Sina Teaching Hospital, Consultative Clinic for Internal Medicine in Mosul city, from Jan. to Dec. 2008. Patients with certain criteria were included in this study. Blood samples were taken from the patients and assay of serum level of malondialdehyde (MDA), total antioxidant status (TAS) and thyroid hormones; [total triiodothyronine (T 3 ), total thyroxine (T 4 ) and thyroid stimulating hormone (TSH)] were done. They then started to receive either valsartan in the first group or captopril in the second group for 2 months after which another set of blood samples were taken and assayed for the same parameters mentioned above, were done. Forty apparently healthy subjects were also included in this study. They were recruited as a control group. Results: Before starting therapy newly diagnosed hypertensive patients, had a significantly higher MDA serum levels and a significantly lower TAS, with non-significant differences in the levels of thyroid hormones (TT 3 , TT 4 & TSH) in comparison to healthy controls. After 2 months of treatment with either captopril or valsartan, there was a significant decrease in MDA serum levels and a significant increase in TAS levels with non-significant effects on thyroid hormonal levels in comparison to pre-therapy stage. Conclusion: Captopril and valsartan therapy improves oxidant / antioxidant status and carry no adverse effects on thyroid function in newly diagnosed patients with mild to moderate hypertension.

show abstract

Section: Discussionmentioning

confidence: 98%

Oxidant / antioxidant status and thyroid function tests in hypertensive patients treated by captopril or valsartan

Othman¹,

Thanoon²

2012

Ann Coll Med Mosul

View full text Add to dashboard Cite

show abstract

“…91 The total cholesterol level remained unchanged, but the HDL-cholesterol level increased and triglycéride levels decreased when prazosin therapy was combined with chlorthalidone treatment. 134 The hy¬ percholesterolemia secondary to chlorthalidone therapy was re¬ stored to normal with the addition of clonidine treatment.132…”

Section: Combination Therapymentioning

confidence: 99%

The Effects of Antihypertensive Agents on Serum Lipids and Lipoproteins

Lardinois

Neuman²

1988

Arch Intern Med

150

View full text Add to dashboard Cite

“…Recent studies indicate that al-adrenoceptor antagonists have a favourable effect on blood lipid profile which is in contrast to the adverse effects of diuretics and 13.adrenoceptor antagonists on lipid metabolism. Thus treatment of hypertensive patients with prazosin is associated with decreases in serum cholesterol and triglyceride levels and increases in the serum high density lipoprotein (HDL) cholesterol and the cholesterol ratio defined as HDL cholesterol/low density lipoprotein cholesterol + very low density lipoprotein cholesterol (Leren et al, 1980;Kirkendall et al, 1978;Lowenstein & Neusy, 1981;Kokubu et al, 1981;Velasco et al, 1981).…”

Section: Smentioning

confidence: 99%

The pharmacological basis for the use of alpha 1‐adrenoceptor antagonists in the treatment of essential hypertension.

Davey¹

1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

Effective preventive antihypertensive therapy is more likely to be achieved with drugs whose mechanisms and sites of action are congruent with the underlying aetiology and pathophysiology than by drugs that lower blood pressure by means unrelated to the process of hypertension. A vast amount of experimental and clinical data exist in favour of the neurogenic hypothesis. Thus hyperactivity of the sympathetic nervous system plays a major role in the pathogenesis and maintenance of essential hypertension and a generalized increase in peripheral vascular resistance is the fundamental haemodynamic abnormality. Reduction in increased sympathetic activity by alpha‐adrenoceptor blockade was one of the earliest pharmacological attempts to treat hypertension. However the discovery of postjunctional alpha 1‐ adrenoceptor antagonists represented the crucially important step in the development of agents to combat specifically adrenergic predominance in essential hypertension. This has yielded antihypertensive drugs of high specificity which preserve feedback control of transmitter noradrenaline release and consequently cause minimal reflex activation of the sympathetic nervous system. These properties have important clinical implications with respect to the therapeutic application of alpha 1‐adrenoceptor antagonists in the treatment of hypertension, and in addition explain why the clinical expectations of the early alpha‐adrenoceptor antagonists remained unfulfilled. Alpha 1‐Adrenoceptor antagonists represent an attractive alternative choice for initial therapy in all grades of hypertension.

show abstract

Effect of Prazosin on Blood Lipids and on Thyroid Function in Hypertensive Patients

Cited by 20 publications

References 0 publications

Oxidant / antioxidant status and thyroid function tests in hypertensive patients treated by captopril or valsartan

Oxidant / antioxidant status and thyroid function tests in hypertensive patients treated by captopril or valsartan

The Effects of Antihypertensive Agents on Serum Lipids and Lipoproteins

The pharmacological basis for the use of alpha 1‐adrenoceptor antagonists in the treatment of essential hypertension.

Contact Info

Product

Resources

About